AR015133A1 - Una forma cristalina de (+/-)1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi)etilamino]-2-propanol, sales farmacologicamente aceptables o formas opticas de lasmismas, un procedimiento para preparar y aislar dicha forma cristalina en forma sustancialmente pura, una composicion farmaceutica que comprende dic - Google Patents
Una forma cristalina de (+/-)1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi)etilamino]-2-propanol, sales farmacologicamente aceptables o formas opticas de lasmismas, un procedimiento para preparar y aislar dicha forma cristalina en forma sustancialmente pura, una composicion farmaceutica que comprende dicInfo
- Publication number
- AR015133A1 AR015133A1 ARP980103547A ARP980103547A AR015133A1 AR 015133 A1 AR015133 A1 AR 015133A1 AR P980103547 A ARP980103547 A AR P980103547A AR P980103547 A ARP980103547 A AR P980103547A AR 015133 A1 AR015133 A1 AR 015133A1
- Authority
- AR
- Argentina
- Prior art keywords
- crystalline form
- pharmaceutical composition
- carvedilol
- propanol
- prepare
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000003287 optical effect Effects 0.000 title abstract 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 title 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 title 1
- OGHNVEJMJSYVRP-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2 OGHNVEJMJSYVRP-UHFFFAOYSA-N 0.000 abstract 6
- 229960004195 carvedilol Drugs 0.000 abstract 5
- 208000019622 heart disease Diseases 0.000 abstract 2
- 241001494479 Pecora Species 0.000 abstract 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002329 infrared spectrum Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Una forma cristalina de (+/-)1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi)-etilamino]-2-propanol, carvedilol que tiene el siguiente modelo de difraccion derayos X obtenido con una radiacion CuKalfa a 2theta = 9,5, 10,8, 12,0, 14,5, 19,6, 21,5, 22,3, y unespectro infrarrojo que tiene picos marcados a 3451 cm-1,en donde el punto de fusion es de aprox. 123-126*C. Sales farmacologicamente aceptables o formas opticas activas de la forma cristalina de carvedilol. Unprocedimiento para preparar y aislar una forma cristalina sustancialmente pura de la forma cristalina de carvedilol.Una composicion farmacéutica, que comprendela forma cristalina de carvedilol en una forma sustancialmente pura, como el ingrediente activo, junto con uno o más adyuvantes ovehículos farmacéuticamenteaceptables; y el uso de la composicion farmacéutica para preparar un medicamento para la profilaxis o el tratamiento de enfermedades cardíacas. La formacristalina de carvedilol se la puede utilizar para evitar y/o tratar enfermedades circulatorias y cardíacas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97112491A EP0893440A1 (en) | 1997-07-22 | 1997-07-22 | Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR015133A1 true AR015133A1 (es) | 2001-04-18 |
Family
ID=8227094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980103547A AR015133A1 (es) | 1997-07-22 | 1998-07-21 | Una forma cristalina de (+/-)1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi)etilamino]-2-propanol, sales farmacologicamente aceptables o formas opticas de lasmismas, un procedimiento para preparar y aislar dicha forma cristalina en forma sustancialmente pura, una composicion farmaceutica que comprende dic |
Country Status (31)
| Country | Link |
|---|---|
| EP (2) | EP0893440A1 (es) |
| JP (1) | JP2001510824A (es) |
| KR (1) | KR100336229B1 (es) |
| CN (1) | CN1125047C (es) |
| AR (1) | AR015133A1 (es) |
| AT (1) | ATE236123T1 (es) |
| AU (1) | AU740453B2 (es) |
| BR (1) | BR9810776A (es) |
| CA (1) | CA2296637C (es) |
| CZ (1) | CZ296947B6 (es) |
| DE (1) | DE69812964T2 (es) |
| DK (1) | DK1000027T3 (es) |
| ES (1) | ES2195366T3 (es) |
| HR (1) | HRP980406A2 (es) |
| HU (1) | HUP0003198A3 (es) |
| IL (1) | IL133677A (es) |
| MA (1) | MA26523A1 (es) |
| MY (1) | MY117734A (es) |
| NO (1) | NO313588B1 (es) |
| NZ (1) | NZ502136A (es) |
| PE (1) | PE96999A1 (es) |
| PL (1) | PL191602B1 (es) |
| PT (1) | PT1000027E (es) |
| RU (1) | RU2202542C2 (es) |
| SI (1) | SI1000027T1 (es) |
| TR (1) | TR200000148T2 (es) |
| TW (1) | TW505631B (es) |
| UY (1) | UY25108A1 (es) |
| WO (1) | WO1999005105A1 (es) |
| YU (1) | YU2200A (es) |
| ZA (1) | ZA986475B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001263813A1 (en) * | 2000-04-03 | 2001-10-15 | F.Hoffmann-La Roche Ag | Concentrated solutions of carvedilol |
| EP1655285A1 (en) * | 2000-06-28 | 2006-05-10 | Teva Pharmaceutical Industries Ltd. | Method for preparation of a crystalline form of carvedilol (form II) |
| HRP20030027A2 (en) | 2000-06-28 | 2004-02-29 | Teva Pharma | Carvedilol |
| JP2004534840A (ja) * | 2001-07-13 | 2004-11-18 | スミスクライン・ビーチャム・コーポレイション | カルベジロール多型体 |
| ATE381924T1 (de) | 2001-09-21 | 2008-01-15 | Egalet As | Feste dispersionen mit kontrollierter freisetzung von carvedilol |
| CA2460486A1 (en) * | 2001-09-28 | 2003-04-10 | F. Hoffmann-La Roche Ag | Pseudopolymorphic forms of carvedilol |
| EP1474133A4 (en) | 2002-01-15 | 2006-02-01 | Teva Pharma | SOLID CRYSTALLINE CARVEDILOL BODIES AND METHODS OF MAKING SAME |
| JP2006500320A (ja) * | 2002-04-30 | 2006-01-05 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | カルベジロール一クエン酸塩一水和物 |
| CN1678305A (zh) | 2002-06-27 | 2005-10-05 | Sb药物波多黎各公司 | 卡维地洛磷酸盐和/或其溶剂合物和/或相应组合物和/或治疗方法 |
| JP2005533822A (ja) * | 2002-06-27 | 2005-11-10 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | 臭化水素酸カルベジロール |
| AU2003275953A1 (en) | 2002-11-08 | 2004-06-07 | Egalet A/S | Controlled release carvedilol compositions |
| ATE495732T1 (de) | 2003-03-26 | 2011-02-15 | Egalet As | Morphin-system mit kontrollierter freisetzung |
| EP1615888A1 (en) * | 2003-04-21 | 2006-01-18 | Matrix Laboratories Ltd | Process for the preparation of carvedilol form-ii |
| SI21616A (sl) * | 2003-09-02 | 2005-04-30 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Nove kristalne oblike karvedilola |
| EP1686986A4 (en) * | 2003-11-25 | 2009-05-27 | Sb Pharmco Inc | CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT |
| ES2333537T3 (es) * | 2004-12-09 | 2010-02-23 | Zach System S.P.A. | Procedimiento de preparacion de carvedilol y sus enantiomeros. |
| EP1781611A1 (en) * | 2005-06-09 | 2007-05-09 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of carvedilol and processes for their preparation |
| US8022094B2 (en) | 2006-06-28 | 2011-09-20 | Teva Pharmaceutical Industries Ltd. | Carvedilol phosphate |
| RU2366653C2 (ru) * | 2006-07-03 | 2009-09-10 | Ооо "Нанокриохимия" | Способ получения рентгеноаморфной модификации карведилола |
| US20080249317A1 (en) * | 2007-04-04 | 2008-10-09 | Apotex Inc. | Novel amorphous form of carvedilol phosphate and processes for the preparation thereof |
| EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| EP2393484A1 (en) | 2009-02-06 | 2011-12-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
| EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2815926A1 (de) * | 1978-04-13 | 1979-10-18 | Boehringer Mannheim Gmbh | Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DE2805404A1 (de) * | 1978-02-09 | 1979-08-16 | Merck Patent Gmbh | 1-aryloxy-3-nitratoalkylamino-2-propanole und verfahren zu ihrer herstellung |
| DE3319027A1 (de) * | 1983-05-26 | 1984-11-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten |
-
1997
- 1997-07-22 EP EP97112491A patent/EP0893440A1/en not_active Withdrawn
-
1998
- 1998-07-15 PE PE1998000626A patent/PE96999A1/es not_active Application Discontinuation
- 1998-07-15 MY MYPI98003245A patent/MY117734A/en unknown
- 1998-07-18 HU HU0003198A patent/HUP0003198A3/hu unknown
- 1998-07-18 YU YU2200A patent/YU2200A/sh unknown
- 1998-07-18 TW TW087111738A patent/TW505631B/zh not_active IP Right Cessation
- 1998-07-18 JP JP2000504104A patent/JP2001510824A/ja active Pending
- 1998-07-18 CA CA002296637A patent/CA2296637C/en not_active Expired - Fee Related
- 1998-07-18 CZ CZ20000221A patent/CZ296947B6/cs not_active IP Right Cessation
- 1998-07-18 AU AU86319/98A patent/AU740453B2/en not_active Ceased
- 1998-07-18 NZ NZ502136A patent/NZ502136A/en unknown
- 1998-07-18 DE DE69812964T patent/DE69812964T2/de not_active Expired - Fee Related
- 1998-07-18 PL PL338432A patent/PL191602B1/pl unknown
- 1998-07-18 ES ES98937576T patent/ES2195366T3/es not_active Expired - Lifetime
- 1998-07-18 DK DK98937576T patent/DK1000027T3/da active
- 1998-07-18 BR BR9810776-3A patent/BR9810776A/pt not_active Application Discontinuation
- 1998-07-18 AT AT98937576T patent/ATE236123T1/de not_active IP Right Cessation
- 1998-07-18 IL IL13367798A patent/IL133677A/en not_active IP Right Cessation
- 1998-07-18 KR KR1020007000667A patent/KR100336229B1/ko not_active Expired - Fee Related
- 1998-07-18 CN CN98807436A patent/CN1125047C/zh not_active Expired - Fee Related
- 1998-07-18 EP EP98937576A patent/EP1000027B1/en not_active Expired - Lifetime
- 1998-07-18 WO PCT/EP1998/004475 patent/WO1999005105A1/en not_active Ceased
- 1998-07-18 PT PT98937576T patent/PT1000027E/pt unknown
- 1998-07-18 SI SI9830442T patent/SI1000027T1/xx unknown
- 1998-07-18 TR TR2000/00148T patent/TR200000148T2/xx unknown
- 1998-07-18 RU RU2000103033/04A patent/RU2202542C2/ru not_active IP Right Cessation
- 1998-07-20 MA MA25178A patent/MA26523A1/fr unknown
- 1998-07-21 ZA ZA9806475A patent/ZA986475B/xx unknown
- 1998-07-21 AR ARP980103547A patent/AR015133A1/es unknown
- 1998-07-22 HR HR97112491.2A patent/HRP980406A2/hr not_active Application Discontinuation
- 1998-07-22 UY UY25108A patent/UY25108A1/es not_active IP Right Cessation
-
2000
- 2000-01-21 NO NO20000301A patent/NO313588B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR015133A1 (es) | Una forma cristalina de (+/-)1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi)etilamino]-2-propanol, sales farmacologicamente aceptables o formas opticas de lasmismas, un procedimiento para preparar y aislar dicha forma cristalina en forma sustancialmente pura, una composicion farmaceutica que comprende dic | |
| NO952132D0 (no) | Farmakologiske aktive pyridin-derivater og deres fremstilling | |
| ES2150889T1 (es) | Una combinacion de glibenclamida-clorhidrato para el tratamiento de la diabetes mellitus de tipo ii. | |
| NO20053782L (no) | Behandling av kreft med 2-deoksyglukose | |
| AR013742A1 (es) | Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida | |
| ES2153862T3 (es) | Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas. | |
| RU2000103033A (ru) | Термодинамически стабильная модификация 1-(4-карбазолилокси)-3-[2-(2-метоксифенокси)этиламино]-2-пропанола, способ ее получения и содержащие ее фармацевтические композиции | |
| MX9305248A (es) | Compuestos de diarilpiperazinoacetamida. | |
| GEP20022763B (en) | 2-(3,5-Bis-Trifluoromethyl-Phenyl)-N-Methyl-N-(6-Morpholin-4-Yl-4-O-Tolyl-Pyridin-3-Yl)-Isobutyramide, Method for its Production and Medicament Containing the Same for Treatment of the Diseases Caused by NK-1 Receptor | |
| DK0502788T3 (da) | Trisubstituerede triaziner og pyrimidiner, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem | |
| AR128066A1 (es) | Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos | |
| PA8587201A1 (es) | Derivados terapeuticos de prolina | |
| AR036689A1 (es) | La forma pseudopolimorfica de (+/-) 1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi) etilamino]-2-propanol o formas opticamente activas o sales farmaceuticamente aceptables de la misma, uso de la misma, una composicion farmaceuticamente aceptable que la comprende, una forma de administracion farmaceuticame | |
| AR021086A1 (es) | Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento. | |
| DE69227583D1 (de) | Arylmorpholine, herstellung und verwendung | |
| NO995944L (no) | Anti-arrytmisk blanding og fremgangsmåter for behandling | |
| MX9702732A (es) | Uso de derivados de indol para el tratamiento de diferentes enfermedades. | |
| AR065528A1 (es) | Forma de dosificacion que comprende 6-(3- coclobutil -2,3,4,5- tetrahidro -1h - benzo (d) azepin -7-iloxi)-n - metil- nicotinamida , metodo para producirla, su uso para preparar un medicamento y solucion o suspension que los comprende | |
| UY26459A1 (es) | 3,4-dihidroquinazolinas 5,6-disustituidas | |
| AR027122A1 (es) | Composicion paa el tratamiento de tejidos danados | |
| PE20011080A1 (es) | Uso de mirtazapina para el tratamiento de trastornos del sueno | |
| RU98111152A (ru) | Применение активного вещества флупиртина или его фармакологически приемлемых солей в качестве лекарственного средства для профилактики и лечения заболеваний, ассоциированных с повреждением клеточной системы гемопоэза | |
| ES2191908T3 (es) | 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido. | |
| MX2021008986A (es) | Metodos de tratamiento de un paciente con enfermedad de parkinson. | |
| CO5170494A1 (es) | Complejo farmaceutico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |